CVS Health Beats Q4 Sales, Reaffirms $7.00–$7.20 EPS Guide
CVS Health reported Q4 sales of $105.69B and adjusted EPS of $1.09, surpassing consensus estimates of $103.59B and $0.99. The company reaffirmed fiscal 2026 guidance of $7.00–$7.20 EPS, cut operating cash flow outlook to at least $9.0B, and forecast revenue of at least $400B.
1. Q4 Financial Beat
CVS Health posted Q4 sales of $105.69 billion, exceeding analyst consensus by over $2 billion, and delivered adjusted earnings of $1.09 per share versus a prior-year $1.19 and a consensus of $0.99.
2. Fiscal 2026 Outlook Reaffirmed
Management affirmed adjusted EPS guidance of $7.00–$7.20, lowered operating cash flow target to at least $9.0 billion from $10.0 billion, and projected revenue of at least $400 billion with operating income between $15.07 billion and $15.41 billion.
3. Analyst Growth Levers
Bank of America notes multiple offset strategies, including Medicare Advantage rate renewals, pharmacy benefit pricing adjustments, share repurchases and margin improvements in Oak Street Health clinics to counter 2027 headwinds.